-
RHEB Neddylation Activates mTORC1 in Liver Cancer
2026-08-15
The reference study identifies RHEB as a non-cullin substrate of the UBE2F–SAG neddylation machinery and shows that modification at K169 strengthens lysosomal localization, GTP binding, and mTORC1 activation. Genetic evidence from cell and liver-specific models links this pathway to steatosis, hepatocellular tumorigenesis, and patient-survival associations.
-
Quinolone–Coumarin Hybrids Against Toxoplasma gondii
2026-08-14
A 2024 Acta Parasitologica study evaluated twelve quinolone–coumarin hybrids derived from fluoroquinolones and novobiocin against intracellular Toxoplasma gondii. QC1, QC3, QC6, and novobiocin showed favorable selectivity and reduced infection, parasite proliferation, and plaque formation in vitro, supporting further lead-optimization studies while leaving target validation and in vivo efficacy unresolved.
-
Triiodothyronine in Cell Viability Assays
2026-08-14
Learn how Triiodothyronine (T3), SKU C6407, can be incorporated into reproducible viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers solubility, vehicle controls, assay interpretation, protocol planning, and reagent-selection criteria for thyroid hormone research.
-
Forskolin Workflows for cAMP and Vascular Research
2026-08-13
Build reproducible cAMP perturbation workflows with Forskolin for stem-cell, neuroendocrine, and vascular assays. This guide connects direct adenylate cyclase activation with the CD36–autophagy-lysosomal framework emerging from vascular injury research, while clearly separating established evidence from testable extensions.
-
Cy5 Goat Anti-Rabbit IgG: Mechanism to Readout
2026-08-13
Learn how the Cy5 Goat Anti-Rabbit IgG (H+L) Antibody converts rabbit-primary assays into interpretable fluorescence data. This guide connects secondary-antibody design with the ASB3–MAVS antiviral pathway while emphasizing controls, signal architecture, and assay limitations.
-
BGJ398: A Developmental Lens on FGFR2 Assays
2026-08-12
BGJ398 (NVP-BGJ398) is a selective FGFR1/2/3 inhibitor with broad value in oncology research. This article shows how developmental evidence on Fgf10–Fgfr2 signaling can sharpen model selection, endpoint timing, and interpretation of FGFR assays.
-
Anlotinib Hydrochloride: Translational Strategy
2026-08-12
Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor that connects VEGFR2-centered angiogenesis biology with PDGFRβ, FGFR1, ERK signaling, and practical translational assay design. This thought-leadership guide shows how to distinguish vascular mechanism from direct tumor-cell toxicity, benchmark anti-angiogenic performance, and build a stronger evidence chain for cancer research.
-
EZ Cap EGFP mRNA 5-moUTP Workflow Guide
2026-08-11
Use EZ Cap EGFP mRNA 5-moUTP as a reproducible fluorescent benchmark for mRNA delivery, translation, viability, and imaging workflows. Its Cap1 structure, 5-moUTP chemistry, and optimized poly(A) tail help separate delivery problems from intrinsic transcript-performance problems.
-
ddATP as a Causal Probe of DNA Replication
2026-08-11
ddATP, or 2',3'-dideoxyadenosine triphosphate, is more than a chain terminator nucleotide: it can help separate DNA synthesis from damage signaling. This article explains its chemistry, assay logic, and interpretation in replication and repair research.
-
REV1–DHX36 Control of G-Quadruplex Tolerance
2026-08-10
The reference study identifies a direct REV1–DHX36 partnership that coordinates G-quadruplex unwinding, replication-fork progression, and suppression of single-stranded DNA gaps. Its two-tier model explains how cells tolerate stabilized G-quadruplex DNA while linking replication stress to ATM/ATR signaling and potential cancer research applications.
-
KU-55933: Selective ATM Kinase Inhibitor
2026-08-09
KU-55933 is a potent and selective ATM kinase inhibitor for DNA damage response research and cancer research. Its reported biochemical potency, cellular effects on Akt signaling, and defined DMSO handling make it useful for mechanistic studies, but experimental concentrations should not be interpreted as clinical efficacy.
-
Antiepileptic Drugs and Human Aromatase Inhibition
2026-08-08
Jacobsen and colleagues evaluated 12 antiepileptic drugs in a human CYP19 aromatase assay and identified lamotrigine among the compounds capable of reducing enzyme activity. The study provides a useful comparative framework for investigating endocrine consequences of antiepileptic exposure, while also showing why recombinant enzyme findings should not be treated as direct evidence of clinical hormone disruption.
-
Baicalin Reactivates Adult Visual Plasticity
2026-08-07
A 2026 NeuroImage study reports that Baicalin reactivates ocular dominance plasticity in adult amblyopic mice, with recovery associated with reduced cortical GABAergic inhibition and perineuronal nets. The work provides a dose-sensitive, experimentally testable framework for combining pharmacological plasticity enhancement with reverse suturing, while leaving human translation and long-term durability unresolved.
-
CD28-ARS2 Axis Controls PKM Splicing and CD8+ T Cell Metabol
2026-08-07
This study identifies the CD28-ARS2 signaling axis as a pivotal regulator of alternative splicing in CD8+ T cells, promoting PKM2 expression and enabling metabolic flexibility for effective antitumor responses. These findings elucidate a distinct mechanism of immunometabolic adaptation, with implications for optimizing T cell-based therapies and metabolic assays.
-
AZD1390: ATM Kinase Inhibitor Workflows for Cancer Radiosens
2026-08-06
AZD1390 is transforming DNA damage response research by enabling precise inhibition of ATM kinase, facilitating radiosensitization in glioma and lung cancer models. This guide demystifies experimental workflows, practical troubleshooting, and protocol enhancements for researchers leveraging this next-generation ATM kinase inhibitor.